Dr. Reidy-Lagunes on FDA Approval of Telotristat Ethyl for Carcinoid Syndrome

Video

Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of telotristat ethyl (Xermelo) as a treatment for carcinoid syndrome in patients with metastatic neuroendocrine tumors (NETs).

Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of telotristat ethyl (Xermelo) as a treatment for carcinoid syndrome in patients with metastatic neuroendocrine tumors (NETs).

Related Videos
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
Elias Jabbour, MD
Shruti Tiwari, MD
Jeffrey P. Townsend, PhD
Marina Baretti, MD
Related Content
Updates and Advances in Early Stage Breast Cancer

Updates and Advances in Early Stage Breast Cancer

April 5th 2023
Article
Manali Kamdar, MD

Dr. Kamdar on the Results of the TRANSFORM Trial in Relapsed/Refractory LBCL

December 11th 2021
Article
Brandon Blue, MD

Dr. Blue on the Utility of Carfilzomib in Relapsed/Refractory Multiple Myeloma

October 1st 2021
Article
Randall Shares How Postoperative Radiotherapy Retains a Role in Soft Tissue Sarcoma

Randall Shares How Postoperative Radiotherapy Retains a Role in Soft Tissue Sarcoma

July 29th 2020
Article
Dr. Jacobson on the Benefit of Axi-Cel in Relapsed/Refractory Follicular Lymphoma

Dr. Jacobson on the Benefit of Axi-Cel in Relapsed/Refractory Follicular Lymphoma

June 11th 2020
Article
Dr. Katz on Determining Low-Risk Disease in Prostate Cancer

Dr. Katz on Determining Low-Risk Disease in Prostate Cancer

June 2nd 2020
Article